This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by F, L. Articles by Z, H. Search for Related Content PubMed PubMed Citation Articles by F, L. Articles by Z, H. Social Bookmarking                         What's this?

A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis

The Nephrology Division, Huashan Hospital, Fudan University, Shanghai, China, lufuming{at}medmail.com.cn

Tu Y

The Nephrology Division, Huashan Hospital, Fudan University, Shanghai, China

Peng X

The Nephrology Division, Huashan Hospital, Fudan University, Shanghai, China

Wang L

The Nephrology Division, Huashan Hospital, Fudan University, Shanghai, China

Wang H

The Nephrology Division, Huashan Hospital, Fudan University, Shanghai, China

Sun Z

The Nephrology Division, Huashan Hospital, Fudan University, Shanghai, China

Zheng H

The Nephrology Division, Huashan Hospital, Fudan University, Shanghai, China

Hu Z

The Nephrology Division, Huashan Hospital, Fudan University, Shanghai, China

Mycophenolate mofetil (MMF) with prednisolone has been associated with high remission rates when used as induction treatment for lupus nephritis. This prospective, multicentre, cohort study investigates the efficacy and safety of this regimen over 24 weeks in 213 Chinese patients with active lupus nephritis (Classes III, IV, V or combination). Baseline activity index (AI) was 6.91 ± 3.33 and chronicity index (CI) was 1.9 ± 1.2. The remission rate was 82.6% at 24 weeks (complete remission, 34.3%; partial remission, 48.4%). There were significant (P < 0.01) improvements in kidney function shown by reductions in proteinuria, serum albumin, serum creatinine and creatinine clearance, as well as in systemic lupus erythematosus disease activity index (SLEDAI) scores. Independent risk factors influencing remission were pathological classification (including Class V and III or Class V and IV nephritis) and elevated serum creatinine at baseline (OR 2.967, 95% CI: 1.479–6.332, P = 0.001 and OR 1.007, 95% CI: 1.002–1.011, P = 0.001, respectively). Patients with concomitant membranous features on biopsy had a lower remission rate than those with Class III and IV nephritis (66.7% vs 87.3%, P = 0.002). Renal biopsy was repeated in 25 patients following treatment. There was a transition to less severe pathological morphologies in majority of subjects. Infections were monitored throughout treatment: eight patients (3.8%) experienced bacterial infections, whereas herpes zoster occurred in seven patients. Nine patients (4.2%) suffered from gastrointestinal upset, which resolved without discontinuation of MMF. One patient became leucopenic, whereas another died from active disease unrelated to kidney symptoms. MMF combined with prednisolone is an effective and well-tolerated induction treatment for patients with active lupus nephritis and for controlling SLE systemic activity.

Key Words: induction treatment • lupus nephritis • mycophenolate mofetil

Lupus, Vol. 17, No. 7, 622-629 (2008)
DOI: 10.1177/0961203308089428


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. K. Li, L.-S. Tam, T. Y. Zhu, M. Li, C. L. Kwok, T. K. Li, Y. Y. Leung, K. C. Wong, and C. C. Szeto Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology, August 1, 2009; 48(8): 892 - 898. [Abstract] [Full Text] [PDF]